Neon Therapeutics, Inc. (NTGN) Analysts See $-0.71 EPS

Analysts expect Neon Therapeutics, Inc. (NASDAQ:NTGN) to report $-0.71 EPS on February, 11.After having $-0.67 EPS previously, Neon Therapeutics, Inc.’s analysts see 5.97 % EPS growth. The stock increased 1.70% or $0.09 during the last trading session, reaching $5.39. About 139,933 shares traded or 12.15% up from the average. Neon Therapeutics, Inc. (NASDAQ:NTGN) has 0.00% since January 12, 2018 and is . It has by 0.00% the S&P500.

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. The company has market cap of $152.61 million. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. It currently has negative earnings.

More notable recent Neon Therapeutics, Inc. (NASDAQ:NTGN) news were published by: which released: “Neon Therapeutics Presents Data from Ongoing Phase 1b NT-001 Clinical Trial at European Society for Medical Oncology 2018 Congress – Nasdaq” on October 22, 2018, also with their article: “Neon Therapeutics Appoints Industry Veteran Robert Bazemore to its Board of Directors – GlobeNewswire” published on November 07, 2018, published: “Neon Therapeutics flames out, shares down 50% from IPO – Seeking Alpha” on September 19, 2018. More interesting news about Neon Therapeutics, Inc. (NASDAQ:NTGN) were released by: and their article: “Neon Therapeutics Closes in on IPO – 24/7 Wall St.” published on June 15, 2018 as well as‘s news article titled: “Neon Therapeutics Named a Top Place to Work in Massachusetts by The Boston Globe – GlobeNewswire” with publication date: November 16, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.